Speed AVF Maturation for Dialysis Patients
Dialysis is a life-saving treatment for patients with end-stage renal disease. Creation of arteriovenous (AV) fistulas are often the best option for permanent vascular access in these patients. Once mature, AV fistulas allow a conduit for regular dialysis, however, failure rates remain high (reaching up to 70%) due to lack of fistula maturation; often requiring secondary surgeries or percutaneous interventions to promote clinical usability.
Up to 70% of AVFs Fail due to lack of maturation.
Alucent aims to improve AV fistula maturation by adding its NVS technology to the AVF procedure – with a particular focus on improving outcomes in the most challenging patients, those with veins with sub optimal diameters.
Pre-Clinical signals demonstrate NVS can potentially promote vein remodeling thus speeding & enhancing the physiological and functional maturation of the AVF – helping patients more rapidly and reliably have regular life-saving dialysis.
Based on histological evidence in pre-clinical research, a hybrid fistula creation including the NVS therapy can reduce potential of injury to the vein due to sudden changes in blood flow and facilitate rapid fistula maturation leading to more successful outcomes.
How It Works
Standard balloon angioplasty is performed to pre-treat the vessel.
Small Molecule Compound Delivery
The NVS photoactivable small molecule compound is delivered to the diseased arterial wall, where it quickly penetrates into and through the arterial wall.
The NVS light fiber is activated. The light source photoactivates the small molecule compound that has permeated into the arterial tissues, creating durable linking within the vessel’s native connective tissue.
The natural scaffold is created and the vessel lumen is restored. The balloon and catheter are removed and standard interventional methods are followed to finalize the procedure.